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Abstract
Responsiveness to change is an important psychometric property of an outcome instrument. Assessment of health-
related quality of life (HRQoL) is critical to outcome assessment after total joint replacement, a surgery aimed at
improving pain, function and HRQoL of the patients undergoing these procedures. In a recent study, Shi et al.
examined the responsiveness to change of various subscales of two instruments, physician-administered Harris Hip
Score and patient self-administered Short Form-36 (SF-36), 6 months after revision total hip arthroplasty. The
responsiveness statistics for both scales were reasonable, higher for Harris Hip Score than SF-36. This is the first
study to examine responsiveness of these instruments in revision THA patients in a systematic fashion.
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Commentary
Outcome measurement is the key to assessment of effi-
cacy/effectiveness of joint arthroplasty, an elective pro-
c e d u r ea i m e da tr e l i e v i n gp a i na n di m p r o v i n gf u n c t i o n ,
health-related quality of life (HRQoL) and mobility.
Instruments used to assess HRQoL outcomes (and func-
tion) following hip arthroplasty can be physician-admi-
nistered disease-specific measures such as Harris Hip
Score (HHS), patient-administered generic assessments
such as Short Form 36 (SF-36), patient-administered
joint-specific instrument such as Oxford hip score or
patient-administered limb-specific instrument such as
Western Ontario and McMaster Osteoarthritis Index
(WOMAC). Use of patient-reported HRQoL/function
outcome measures is considered the gold standard for
the assessment of patient-reported outcomes (PROs). A
major National Institute of Health Initiative, the Patient-
Reported Outcome Measurement Information System
(PROMIS), is focused on this aspect of outcome assess-
ment [1]. While a variety of outcome instruments are
used and reported in studies of hip arthroplasty, HHS is
t h em o s tc o m m o n l yu s e di n s t r u m e n ti ns t u d i e so fh i p
arthroplasty [2].
In a recent issue of the journal, Shi et al. assessed the
responsiveness and minimal important differences
(MID) [3]. Specifically, they compared two instruments,
physician-administered HHS and patient-reported SF-
36. Sixty-seven patients completed surveys pre-operative
and 6-month post-revision total hip arthroplasty (THA).
Two measures of responsiveness, i.e., the effect size
(mean change from baseline to 6-months divided by the
standard deviation of baseline scores) and standardized
response means (ratio of mean change and standard
deviation of change scores) were significantly more for
HHS pain and function subscales than for the respective
comparable SF-36 subscales, bodily pain and physical
functioning. MID, estimated as 0.5 times standard devia-
tion, was 2.3 for HHS physical function (range 0-44) and
3.4 for HHS pain scales (range 0-46) compared to 3.2
for SF-36 physical function (range 0-100) and 14.9 for
SF-36 bodily pain (range 0-100) subscales. Several find-
ings of this important study deserve further discussion
and need to be viewed in context of published literature
in this area. These findings must be interpreted while
considering the study limitations including a small study
sample size, potential generalizability issues to US and
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any medium, provided the original work is properly cited.European populations and lack of validation data regard-
ing the Chinese version of HHS.
This study provides comparison of responsiveness of
two common HRQoL assessment tools used in the
patients with revision THA, the HHS and SF-36. Use of
Generalized estimating equations (GEE) technique is a
particular strength of this analysis, since it allows for
allows for correlation without the need for defining a
model for dependency of variables. Several previous stu-
dies have examined these instruments in patients with
primary THA and found that disease-specific instru-
ments were more responsive than generic instruments
[4]. The findings from this study extend these findings
to the revision THA cohorts. Although, not directly
comparable due to differences in study populations and
their characteristics, the responsiveness statistics esti-
mated in previous studies in primary THA [4-7] are in
the same range as in this study [3]. Significant improve-
ments in HRQoL similar to those observed in patients
with primary THA have been reported in patients with
revision THA. It is reassuring that same patient-
reported outcome instruments are responsive in both
primary and revision THA cohorts. This is a major
advantage implying that similar instruments can be
employed in these cohorts decreasing the variability
introduced by the use of multiple instruments. As a
rough guide, an effect size of 0.20-0.49 represents a
small change, 0.50-0.79 a medium change, and ≥ 0.80, a
l a r g ec h a n g e[ 8 ] .I m p o r t a n t l y ,t h ee f f e c ts i z e sf o rH H S
pain, HHS physical function scales and SF-36 physical
functioning subscales exceeded 0.8 (large effect size)
and were higher for HHS compared to SF-36. The effect
size was 0.41 for SF-36 bodily pain (small effect size). A
systematic review found effect sizes ranging 2.35-3.91
for physician-administered measures were higher than
the effect sizes for patient-administered measures in
patients who underwent total knee arthroplasty [9], that
ranged 1.27-1.62. The exact reasons for greater effect
sizes with physician-administered instruments are
unclear. Potential explanations include patient’sd e s i r e
to report a better health condition when queried by the
physician and physician’s assessment bias. In a recent
study, we found that patients report less pain in physi-
cians’ office when queried by the health care provider
compared to that pain reported by them by a mailed
survey completed at home [10]. Regardless of the rea-
sons, the differences in physician versus patient-admi-
nistered surveys are obvious. The current gold standard
in PROs is patient-reported assessments, and therefore
one can expect that use of patient-reported assessments
will increase over time. Patient self-administered surveys
are also more practical than a physician-administered
survey, both in clinical practice and clinical research
settings.
These findings should prompt more studies to exam-
ine the comparative responsiveness of other measures in
revision THA patients, which might allow the discovery
of the most sensitive HRQoL instruments for use in
clinical trials for treatment comparisons. The respon-
siveness of HRQoL instruments would be expected to
be higher with a surgical intervention such as revision
THA surgery compared to a medical intervention for
pain relief in the same cohort of patients.
The responsiveness of role limitations subscales were
greater as compared to pain and physical function sub-
scales based on effect size and standardized response
mean. This is not unexpected considering that both lim-
itation scales are single questions as opposed to multiple
questions in physical functioning subscale and the pre-
operative score on one role limitation subscale (role
physical) was lower compared to physical function and
pain subscale scores. A lower preoperative value allows
for a greater chance of improvement and less of a ceil-
ing effect. This observation is in agreement with signifi-
cant and important changes noted in these scales in
previous studies [7,11,12].
The study provided minimally important difference
(MID) estimates based on statistical method using 0.5
times standard deviation of the mean difference. The
estimation of MID is in contrast to the methods used to
define minimal clinically important difference (MCID)
using patient-based anchor such as patient global assess-
ment of change. Although there is an ongoing debate
whether estimates derived from a statistical approach
such as 0.5 SD are similar to those derived using a
patient-reported anchor-based approach, in several
instances they may be very similar. A more important
point to keep in mind is that MID or MCID should not
be thought as an absolute number, but at best an esti-
mate derived from a given sample. It can differ based on
s t u d ys e t t i n g ,s e v e r i t yo ft h ed i s e a s ea n dt h et y p eo f
intervention being assessed. A detailed discussion of
issues related to MCID assessment and other aspects of
HRQoL assessments in patients with arthroplasty with a
focus on problems and solutions has been recently pub-
lished [13]. An approach to achieving consensus in out-
come assessments in patients with arthroplasty is
needed and was discussed by Riddle and colleagues in a
recent publication [14].
Conclusions: What is the take home message?
This study provides evidence that both HHS and SF-36
are responsive to change in patients undergoing revision
THA and can be used in HRQoL assessment for longi-
tudinal studies in patients with revision THA. This
study also provides estimates of MID, which can be
used to power future studies comparing different surgi-
c a la p p r o a c h e so ri m p l a n tt y p e si np a t i e n t su n d e r g o i n g
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mary or secondary outcome measures. The finding that
the disease-specific HHS was more sensitive to change
than generic SF-36 is not surprising and should not be
interpreted as a rationale to not include SF-36 in the
assessment of patients with revision THA. In fact, a gen-
eric instrument such as SF-36 captures HRQoL domains
differently than the disease-specific HHS, and can com-
pliment the information obtained by the use of HHS. In
addition, availability of population norms for SF-36 and
availability of scores for other health conditions and
chronic diseases allows comparisons of HRQoL gains
across disease conditions, which plays an important role
in health care policy. In conclusion, this study advances
our knowledge in HRQoL assessment in patients with
hip arthroplasty, and provides clinicians with tools for
assessment of outcomes in clinical practice and
researchers and trialists with additional data to design
more robust studies in the future.
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